InsiderTrades.com logo
Lawrence Otto Klein net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Lawrence Klein Biography and Net Worth

CEO of Oruka Therapeutics

Before joining Oruka, he was a Partner at Versant Ventures, where he invested in and helped grow early-stage biotechnology companies. He previously was a critical member of the CRISPR Therapeutics leadership team and helped grow the company into one of the most recognized innovative biotechnology companies in the industry. During his seven-year tenure with CRISPR, he served as Chief Business Officer before also taking on the role of Chief Operating Officer. In these roles he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs, and contribute to building the team. Prior to CRISPR, he served a variety of clients in the biopharma industry as an Associate Partner at McKinsey & Company.

Dr. Klein holds a PhD in biophysics from Stanford University, where his research focused on T cell immunology.

What is Lawrence Otto Klein's net worth?

The estimated net worth of Lawrence Otto Klein is at least $38.31 million as of March 16th, 2026. Klein owns 927,309 shares of Oruka Therapeutics stock worth more than $38,307,135 as of March 17th. This net worth approximation does not reflect any other assets that Klein may own. Learn More about Lawrence Otto Klein's net worth.

How do I contact Lawrence Otto Klein?

The corporate mailing address for Klein and other Oruka Therapeutics executives is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. Oruka Therapeutics can also be reached via phone at 720-940-2100 and via email at [email protected]. Learn More on Lawrence Otto Klein's contact information.

Has Lawrence Otto Klein been buying or selling shares of Oruka Therapeutics?

During the past quarter, Lawrence Otto Klein has sold $71,407.70 in shares of Oruka Therapeutics stock. Most recently, Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a transaction totalling $71,407.70. Following the completion of the sale, the chief executive officer now directly owns 927,309 shares of the company's stock, valued at $38,297,861.70. Learn More on Lawrence Otto Klein's trading history.

Who are Oruka Therapeutics' active insiders?

Oruka Therapeutics' insider roster includes Joana Goncalves (Chief Medical Officer), and Lawrence Klein (CEO). Learn More on Oruka Therapeutics' active insiders.

Are insiders buying or selling shares of Oruka Therapeutics?

In the last year, insiders at the sold shares 6 times. They sold a total of 30,765 shares worth more than $1,063,844.51. The most recent insider tranaction occured on March, 16th when CEO Lawrence Otto Klein sold 1,729 shares worth more than $71,407.70. Insiders at Oruka Therapeutics own 24.7% of the company. Learn More about insider trades at Oruka Therapeutics.

Information on this page was last updated on 3/16/2026.

Lawrence Otto Klein Insider Trading History at Oruka Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2026Sell1,729$41.30$71,407.70927,309View SEC Filing Icon  
See Full Table

Lawrence Otto Klein Buying and Selling Activity at Oruka Therapeutics

This chart shows Lawrence Otto Klein's buying and selling at Oruka Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oruka Therapeutics Company Overview

Oruka Therapeutics logo
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $41.31
Low: $39.70
High: $42.30

50 Day Range

MA: $33.22
Low: $26.40
High: $41.75

2 Week Range

Now: $41.31
Low: $5.49
High: $42.41

Volume

645,396 shs

Average Volume

465,772 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A